Aktuellt
SENASTE
Redeye provides an updated view on Scandion Oncology, following the company presenting its refocused strategy at its capital markets day and announcing PANTAX phase Ib readout’s delay into Q2-Q3 2022. Looking forward, we regard CORIST phase II part 2/3 and PANTAX phase Ib top-line data as the primary catalysts for Scandion in 2022.
LÄS MER
